SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Landen M) ;srt2:(2010-2014)"

Sökning: WFRF:(Landen M) > (2010-2014)

  • Resultat 61-70 av 87
  • Föregående 1...3456[7]89Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  • Söderlund, Johan, et al. (författare)
  • Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder.
  • 2010
  • Ingår i: Journal of psychiatry & neuroscience : JPN. - 1488-2434. ; 35:6
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: In recent years, a role for the immune system in the pathogenesis of psychiatric diseases has gained increased attention. Although bipolar disorder appears to be associated with altered serum cytokine levels, a putative immunological contribution to its pathophysiology remains to be established. Hitherto, no direct analyses of cerebrospinal fluid (CSF) cytokines in patients with bipolar disorder have been performed. Methods: We analyzed CSF cytokine concentrations in euthymic patients with diagnosed bipolar dis order type I (n = 15) or type II (n = 15) and healthy volunteers (n = 30) using an immunoassay-based protein array multiplex system. Results: The mean interleukin (IL)-1ß level (4.2 pg/mL, standard error of the mean [SEM] 0.5) was higher and the IL-6 level (1.5 pg/mL, SEM 0.2) was lower in euthymic bipolar patients than in healthy volunteers (0.8 pg/mL, SEM 0.04, and 2.6 pg/mL, SEM 0.2, respect ively). Patients with 1 or more manic/hypomanic episodes during the last year showed significantly higher levels of IL-1ß (6.2 pg/mL, SEM 0.8; n = 9) than patients without a recent manic/hypomanic episode (3.1 pg/mL, SEM 1.0; n = 10). Limitations: All patients were in an euthymic state at the time of sampling. Owing to the large variety of drugs prescribed to patients in the present study, influence of medication on the cytokine profile cannot be ruled out. Conclusion: Our findings show an altered brain cytokine profile associated with the manifestation of recent manic/hypomanic episodes in patients with bipolar disorder. Although the causality remains to be established, these findings may suggest a pathophysiological role for IL-1ß in bipolar disorder.
  •  
62.
  •  
63.
  • Tidemalm, D., et al. (författare)
  • Attempted Suicide in Bipolar Disorder: Risk Factors in a Cohort of 6086 Patients
  • 2014
  • Ingår i: Plos One. - 1932-6203. ; 9:4
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: Bipolar disorder is associated with high risk of self-harm and suicide. We wanted to investigate risk factors for attempted suicide in bipolar patients. Method: This was a cohort study of 6086 bipolar patients (60% women) registered in the Swedish National Quality Register for Bipolar Disorder 2004-2011 and followed-up annually 2005-2012. Logistic regression was used to calculate adjusted odds ratios for fatal or non-fatal attempted suicide during follow-up. Results: Recent affective episodes predicted attempted suicide during follow-up (men: odds ratio = 3.63, 95% Cl = 1.76-7.51; women: odds ratio = 2.81, 95% Cl = 1.78-4.44), as did previous suicide attempts (men: odds ratio = 3.93, 95% Cl = 2.48-6.24; women: odds ratio = 4.24, 95% Cl = 3.06-5.88) and recent psychiatric inpatient care (men: odds ratio = 3.57, 95% Cl = 1.59-8.01; women: odds ratio = 2.68, 95% Cl = 1.60-4.50). Further, those with many lifetime depressive episodes were more likely to attempt suicide. Comorbid substance use disorder was a predictor in men; many lifetime mixed episodes, early onset of mental disorder, personality disorder, and social problems related to the primary group were predictors in women. Conclusion: The principal clinical implication of the present study is to pay attention to the risk of suicidal behaviour in bipolar patients with depressive features and more severe or unstable forms of the disorder.
  •  
64.
  • Viktorin, Alexander, et al. (författare)
  • The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer
  • 2014
  • Ingår i: American Journal of Psychiatry. - Arlington, USA : American Psychiatric Publishing. - 0002-953X. ; 171:10, s. 1067-1073
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: This study examined the risk of antidepressant-induced manic switch in patients with bipolar disorder treated either with antidepressant monotherapy or with an antidepressant in conjunction with a mood stabilizer.Method: Using Swedish national registries, the authors identified 3,240 patients with bipolar disorder who started treatment with an antidepressant and had no antidepressant treatment during the previous year. Patients were categorized into those receiving antidepressant monotherapy and those receiving an antidepressant plus a mood stabilizer. A within-individual design was used to control for confounding by disorder severity, genetic makeup, and early environmental factors. Cox regression analyses conditioned on individual were used to compare the rate of mania 0-3 months and 3-9 months after the start of antidepressant treatment with a preceding non-treatment period.Results: Nearly 35% of the patients were treated with antidepressant monotherapy. The increased risk of treatment-emergent mania was confined to patients on antidepressant monotherapy (hazard ratio=2.83, 95% CI=1.12, 7.19). Among patients treated with a concurrent mood stabilizer, no acute change in risk of mania was observed during the 3 months after the start of antidepressant treatment (hazard ratio=0.79, 95% CI=0.54, 1.15), and a decreased risk was observed during the period 3-9 months after treatment initiation (hazard ratio=0.63, 95% CI=0.42, 0.93).Conclusions: In this national registry study, antidepressant monotherapy was associated with an increased risk of mania. However, no risk of mania was seen in patients receiving an antidepressant while treated with a mood stabilizer. The results highlight the importance of avoiding antidepressant monotherapy in the treatment of bipolar disorder.
65.
  •  
66.
  •  
67.
  •  
68.
  •  
69.
  • Ekman, M., et al. (författare)
  • PMH30 The Societal Cost of Depression: Evidence from 10,000 Swedish Patients in Psychiatric Care
  • 2012
  • Ingår i: Value in Health. - 1098-3015. ; 15:4, s. A87-A87
  • Konferensbidrag (refereegranskat)abstract
    • Objectives Depression is a major health problem. Previous studies on the cost of depression have mainly taken a primary care perspective. Such studies do not include all patients with depression, and should be completed by cost estimates from psychiatric care. The objectives of this study were to estimate the annual societal cost of depression per patient in psychiatric care in Sweden, and to relate costs to disease severity, depressive episodes, hospitalization, and patient functioning. Methods Retrospective resource use data in inpatient and outpatient care for 2006-2008, as well as ICD-10 diagnoses and Global Assessment of Functioning (GAF), were obtained from Northern Stockholm psychiatric clinic with a catchment area including 47% of the adult inhabitants in Stockholm city. This data set was combined with national register data on prescription pharmaceuticals and sick leave to estimate the societal cost of depression. Results The study included 10,593 patients (63% women). The average annual societal cost per patient was around USD 21,000 in 2006-2008. The largest cost item was indirect costs due to productivity losses (89%), and the second largest was outpatient care (6%). Patients with mild, moderate or severe depression had an average cost of approximately USD 18,000, USD 21,000, and USD 29,000, respectively. Total costs were significantly higher during depressive episodes, for patients with co-morbid psychosis or anxiety, for hospitalized patients, and for patients with low GAF scores. Conclusions The largest share of societal costs for patients with depression in psychiatric care is indirect. The total costs were higher than previously reported from a primary care setting, and strongly related to hospitalization, episodes of active depression, and global functioning. This suggests that effective treatment and rehabilitation that avoid depressive episodes and hospitalization may not only improve patient health, but also reduce the societal cost of depression.
  •  
70.
  • Ekman, M., et al. (författare)
  • The societal cost of bipolar disorder in Sweden
  • 2013
  • Ingår i: Social Psychiatry and Psychiatric Epidemiology. - 0933-7954. ; 48:10, s. 1601-1610
  • Tidskriftsartikel (refereegranskat)abstract
    • There is a lack of comprehensive cost-of-illness studies in bipolar disorder, in particular studies based on patient-level data. The purpose of this study was to estimate the societal cost of bipolar disorder and to relate costs to disease severity, depressive episodes, hospitalisation and patient functioning. Retrospective resource use data in inpatient and outpatient care during 2006-2008, as well as ICD-10 diagnoses and Global Assessment of Functioning (GAF) scores, were obtained from the Northern Stockholm psychiatric clinic with a catchment area including 47 % of the adult inhabitants in Stockholm. This dataset was combined with national register data on prescription pharmaceuticals and sick leave to estimate the societal cost of bipolar disorder. The study was conducted from a societal perspective, with indirect costs valued according to the human capital method. The average annual cost per patient was a,not sign28,011 in 2008 (n = 1,846). Indirect costs due to sick leave and early retirement represented 75 %, inpatient costs 13 %, outpatient costs 8 %, pharmaceuticals 2 % and community care another 2 % of the total cost. Total costs were considerably higher during mood episodes (six times higher than in remission), for hospitalised patients (a,not sign55,500 vs. a,not sign22,200) and for patients with low GAF scores. The high cost of bipolar disorder is driven primarily by indirect costs. Costs were strongly associated with mood episodes, hospitalisations and low GAF scores. This suggests that treatment that reduces the risk for relapses and hospitalizations and improve functioning may decrease both the societal cost of bipolar disorder and patient suffering.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 61-70 av 87
  • Föregående 1...3456[7]89Nästa
Åtkomst
fritt online (9)
Typ av publikation
tidskriftsartikel (67)
konferensbidrag (19)
annan publikation (1)
Typ av innehåll
refereegranskat (65)
övrigt vetenskapligt (22)
Författare/redaktör
Landen, M, (73)
Landén, Mikael, 1966 ... (46)
Lichtenstein, P, (13)
Langstrom, N, (11)
Lichtenstein, Paul, (10)
Zetterberg, H (6)
visa fler...
Jakobsson, J. (6)
Hultman, C. M. (6)
Muller-Myhsok, B (5)
Blennow, K (5)
Sklar, P (5)
Ekman, M (5)
Ekman, C-J (4)
Långström, Niklas (4)
Ryden, E (4)
Ekman, Carl-Johan (4)
Sellgren, Carl (4)
Hultman, CM, (4)
Osby, U, (4)
Stahle, M, (4)
Ripke, S (4)
Schalling, M, (4)
Sullivan, Patrick F. (4)
Cichon, S (4)
Rietschel, M (4)
Leboyer, M. (4)
Sullivan, PF, (3)
Johansson, A (3)
Ingvar, M (3)
Corvin, A (3)
Djurovic, S (3)
Craddock, N (3)
Magnusson, PKE, (3)
Blennow, Kaj, 1958-, (3)
Zetterberg, Henrik, ... (3)
Nikamo, P, (3)
Andreassen, Ole A., (3)
Boomsma, Dorret I., (3)
Cichon, Sven, (3)
Nothen, MM (3)
Backlund, L, (3)
Mattheisen, M (3)
Wetterberg, L. (3)
Lundh, Anna (3)
Etain, B (3)
Montgomery, GW (3)
Larsson, Henrik, 197 ... (3)
Johansson, V (3)
Gill, M. (3)
McQuillin, A (3)
visa färre...
Lärosäte
Karolinska Institutet (82)
Göteborgs universitet (53)
Uppsala universitet (3)
Örebro universitet (3)
Lunds universitet (2)
Linköpings universitet (2)
visa fler...
Umeå universitet (1)
Stockholms universitet (1)
Mälardalens högskola (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (87)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (57)
Lantbruksvetenskap (1)
Samhällsvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy